QNRX

Quoin

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 0

Sell signal 1

Bearish Engulfing

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About QNRX

Quoin Pharmaceuticals, Ltd.

A specialty pharmaceutical company focused on rare and orphan diseases

Industry

Biological Technology

Established Date

08/04/1986

Listing Date

07/29/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.quoinpharma.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

42127 Pleasant Forest Court, Ashburn, VA 20148-7349

Business

Introduction

Quoin Pharmaceuticals, Ltd., was established by the laws of the State of Israel on August 4, 1986. Between 1986 and 2013, the company underwent several name changes, most recently on August 28, 2013, when the company changed its current name from T.R.F. Capital Ltd. The Company is a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for the treatment of rare and orphan diseases. The company's initial focus is to develop products using proprietary own and licensed drug delivery technologies that may help address rare inherited skin diseases, especially those for which there are currently no approved treatments or cures.

Company Financials

EPS

QNRX has released its 2024 Q4 earnings. EPS was reported at -0.35, versus the expected -0.43, beating expectations. The chart below visualizes how QNRX has performed over recent quarters, highlighting trends in earnings surprises.